Edgar Filing: CORCEPT THERAPEUTICS INC - Form 4

			ng. oc			LU		0 101114				
CORCEPT Form 4 March 07, 2	THERAPEUTIC	CS INC										
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION										OMB APPROVAL		
	•••• UNITED) STATES					NGE C	OMMISSION	OMB Number:	3235-0287		
	this box		••	asiningto	shington, D.C. 20549					January 31,		
if no lo subject Section Form 4	to SIAIE.	MENT OI	F CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES						Expires: 20 Estimated average burden hours per response			
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940												
(Print or Type	e Responses)											
1. Name and ENRIGHT	Symbol					5. Relationship of Reporting Person(s) to ssuer						
			CORCEPT THERAPEUTICS INC [CORT]					(Check all applicable)				
(Last)	3. Date of Earliest Transaction					X_ DirectorX_ 10% Owner Officer (give title Other (specify						
C/O LONGITUDE CAPITAL PARTNERS, LLC, 800 EL 03/05/2014 below) below) below)												
CAMINO	REAL, SUITE 2	20	4 70 4					< + + + + + + + +		•		
	(Street)	Filed(Month/Day/Year) Ap _X				 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 						
	PARK, CA 94025							Person				
(City)	(State)	(Zip)					-	iired, Disposed of		•		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deeme Execution I any (Month/Da	Date, if Transactionor Disposed of (D) Code (Instr. 3, 4 and 5) y/Year) (Instr. 8) (A) or				5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code V	Amount	(D)	Price			By		
Common Stock	03/05/2014			S	70,063	D	\$ 4.0098 (1)	13,175,781 (2)	Ι	Longitude Venture Partners, L.P. (3)		
Common Stock	03/05/2014			S	1,404	D	\$ 4.0098 (1)	186,325 <u>(4)</u>	I	By Longitude Capital Associates, L.P. (5)		

Edgar Filing: CORCEPT THERAPEUTICS INC - Form 4

Common Stock	03/06/2014	S	164,800	D	\$ 4.0007 (<u>6)</u>	13,010,981 (2)	Ι	By Longitude Venture Partners, L.P. (3)
Common Stock	03/06/2014	S	3,303	D	\$ 4.0007 (<u>6)</u>	183,022 <u>(4)</u>	I	By Longitude Capital Associates, L.P. (5)
Common Stock	03/07/2014	S	10,225	D	\$4	13,000,756 (2)	I	By Longitude Venture Partners, L.P. (<u>3)</u>
Common Stock	03/07/2014	S	205	D	\$4	182,817 <u>(4)</u>	Ι	By Longitude Capital Associates, L.P. (5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	7. Titl Amou Under Secur (Instr.	unt of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Owne Follo Repo Trans (Instr
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address

Relationships

Edgar Filing: CORCEPT THERAPEUTICS INC - Form 4

Х

Director 10% Owner Officer Other

ENRIGHT PATRICK G C/O LONGITUDE CAPITAL PARTNERS, LLC 800 EL CAMINO REAL, SUITE 220 MENLO PARK, CA 94025

X

Signatures

**Signature of

/s/ Patrick G. 03/07/2014 Enright

Date

Reporting Person Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Reflects sales of common stock executed in multiple transactions at prices ranging from \$4.00 to \$4.07. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission

- (1) staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected.
- (2) Does not include warrants held by Longitude Venture Partners, L.P. ("LVP") to purchase 3,091,479 shares of common stock.

Reflects transactions and holdings of shares of common stock of the Issuer held of record by LVP. Patrick G. Enright is a managing member of Longitude Capital Partners, LLC ("Longitude Capital"), the sole general partner of LVP. Mr. Enright serves on the Board of

- (3) Interformed Capital Fainers, EEC (Example Capital), the sole general parties of EVT. Wr. Enright serves of the Doard of Directors of the Issuer as the nominee of LVP. Mr. Enright disclaims beneficial ownership of the securities of the Issuer held of record by LVP, except to the extent of his pecuniary interest therein.
- (4) Does not include warrants held by LCA to purchase 26,583 shares of common stock.

Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Capital Associates, L.P. ("LCA"). Patrick G. Enright is a managing member of Longitude Capital, the sole general partner of LCA. Mr. Enright serves on the Board of

(5) Trainer of the Issuer as the nominee of LVP. Mr. Enright disclaims beneficial ownership of the securities of the Issuer held of record by LCA, except to the extent of his pecuniary interest therein.

Reflects sales of common stock executed in multiple transactions at prices ranging from \$4.00 to \$4.01. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission

(6) weighted average price. The reporting person hereby undertakes to provide upon request to the security said Exchange commission
 staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected.

Remarks:

All of the sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.